When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report
Abstract Background The advent of biologics has resulted in major progress in the treatment of severe T2 high asthmatics. There are currently several classes of biologics approved for severe asthma including anti-immunoglobulin E, anti-interleukin-5/interleukin 5R, anti-interleukin 4/interleukin 13R...
| Main Authors: | , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
BMC
2024-01-01
|
| 丛编: | Journal of Medical Case Reports |
| 主题: | |
| 在线阅读: | https://doi.org/10.1186/s13256-023-04255-8 |